ArticleThe Journal of urology2025

Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.

Neal D Shore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.